Related Experiment Videos
Systemic lupus erythematosus in the intensive care unit
Rishi Raj1, Susan Murin, Richard A Matthay
1Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Desk A-90, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Critical Care Clinics
|November 7, 2002
Summary
Systemic lupus erythematosus (SLE) patients face high risks from infections, which can mimic disease flares. Careful infection diagnosis is crucial before intensifying immunosuppressive therapy to prevent severe complications and improve survival rates in SLE management.
Area of Science:
- Rheumatology and Immunology
- Infectious Diseases in Autoimmune Conditions
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem organ involvement, leading to significant morbidity and mortality.
- Infections represent the primary cause of morbidity and mortality in SLE patients, often complicating disease management.
- The immunosuppressive therapies used for SLE can increase susceptibility to infections, creating a challenging clinical scenario.
Purpose of the Study:
- To emphasize the critical need for meticulous exclusion of infections in SLE patients presenting with potential disease exacerbations.
- To highlight the risks associated with immunosuppressive therapy in the presence of undiagnosed infections.
- To review current therapeutic approaches for SLE and discuss the need for further research into optimal treatment strategies.
Main Methods:
- Review of clinical management principles for SLE patients, focusing on differential diagnosis between infection and disease flares.
- Discussion of established and emerging therapeutic agents, including corticosteroids, cyclophosphamide, and plasmapheresis.
- Analysis of recent findings on survival rates and identification of gaps in evidence regarding comparative therapeutic trials.
Main Results:
- Infections can present insidiously, mimicking SLE flares, necessitating rigorous diagnostic evaluation.
- Aggressive immunosuppression for presumed SLE flares can lead to severe consequences if an underlying infection is present.
- While some studies suggest improved survival with current treatments, these findings require further validation through controlled trials.
Conclusions:
- Distinguishing between SLE exacerbations and infections is paramount for appropriate patient management and to avoid detrimental therapeutic decisions.
- Current treatment strategies involve corticosteroids and various immunosuppressants, but optimal therapeutic regimens remain undefined.
- Further controlled clinical trials are essential to compare different therapeutic options and establish evidence-based guidelines for SLE management.